New PET scan could predict which breast cancer patients respond to targeted therapy
NCT ID NCT02827877
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether a special PET scan using copper Cu64-DOTA-trastuzumab can predict how well HER2-positive breast cancer responds to trastuzumab and pertuzumab before surgery. The study involves 18 women with locally advanced HER2-positive breast cancer. The goal is to see if the scan can identify who will have a complete response, potentially guiding more personalized treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Copper Cu 64-DOTA-Trastuzumab (a radioactive tracer for PET imaging)
- What this could lead to
- If successful, this imaging method could help doctors quickly identify which patients will benefit from trastuzumab and pertuzumab, avoiding ineffective treatments.
- What could go wrong
- This is a small early-phase study with only 18 participants, so results may not apply to all patients. The imaging technique may not accurately predict response in everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can radiation replace surgery for cancer spread to lymph nodes?
- Major trial pits three chemo drugs against each other for advanced breast cancer
- Triple threat: new combo shows promise against tough breast cancer
- Could adding carboplatin to chemo keep triple-negative breast cancer away?
- Immune booster before chemo shows promise for tough breast cancer
- New hope for Hard-to-Treat breast cancer: immune cocktails enter trial